Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | TSHR | P16473 | 1/20 | 0.59 |
| ▸ | FASN | P49327 | 1/20 | 0.52 |
| ▸ | FAAH | O00519 | 7/20 | 0.47 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13370196 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL1239783 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL9696421 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL19063519 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL18398897 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL18398895 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL17479081 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL11030145 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL3130547 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 | |
| SCHEMBL1237969 | 1.00 | ALDH1A1 (0.59) | ALDH1A1TSHRFASNFAAHTRPV1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | claimed |
| US-20240099976-A1 | BLENDED FORMULATIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2024-03-28 | — | — | US | disclosed |
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | NIPPON SHOKUBAI CO., LTD. (JP) | 2024-01-11 | — | — | US | disclosed |
| US-11547665-B2 | Multiphasic compositions | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2023-01-10 | — | — | US | disclosed |
| EP-3954361-A1 | MULTIPHASIC COMPOSITIONS | Sequessome Technology Holdings Limited (MT) | 2022-02-16 | — | — | EP | disclosed |
| US-20210393655-A1 | Vesicular Formulations for Use in the Treatment of Pain or Reduced Mobility of a Joint | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-12-23 | — | — | US | disclosed |
| EP-3316857-B1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-08-04 | — | — | EP | disclosed |
| EP-3316856-B1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (MT) | 2021-04-07 | — | — | EP | disclosed |
| US-20210023007-A1 | BLENDED FORMULATIONS | SEQUESSOME TECH HOLDINGS LIMITED (US) | 2021-01-28 | — | — | US | disclosed |
| US-20210007989-A1 | MULTIPHASIC COMPOSITIONS | SEQUESSOME TECHNOLOGY HOLDINGS LIMITED (MT) | 2021-01-14 | — | — | US | disclosed |
| US-7820720-B2 | Topical terbinafine formulations and methods of administering same for the treatment of fungal infections | TDT LIMITED (MT) | 2010-10-26 | — | — | US | disclosed |
| WO-2010090654-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TDT, LTD. (MT) | 2010-08-12 | — | — | WO | disclosed |
| US-20100197621-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | TARGETED DELIVERY TECHNOLOGIES LIMITED (MT) | 2010-08-05 | — | — | US | disclosed |
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | CEVC GREGOR | 2010-04-29 | — | — | US | disclosed |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT LIMITED (MT) | 2010-04-08 | — | — | US | disclosed |
| WO-2010010470-A2 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | TDT, LTD (MT) | 2010-01-28 | — | — | WO | disclosed |
| US-20020048596-A1 | PREPARATION FOR THE TRANSPORT OF AN ACTIVE SUBSTANCE ACROSS BARRIERS | IDEA AG (DE) | 2002-04-25 | — | — | US | disclosed |
| EP-0708645-A1 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1996-05-01 | — | — | EP | disclosed |
| WO-1995024199-A2 | USE OF COMPOUNDS WHICH INHIBIT PHOSPHATIDIC ACID FORMATION FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF CANCER | CELL THERAPEUTICS, INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| EP-0503508-A1 | Vesicles and polymeric vesicles | Kao Corporation (JP) | 1992-09-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240009092-A1 | COSMETIC COMPOSITION AND COSMETIC QUASI-DRUG INCLUDING LIPID PARTICLES CONTAINING PHOSPHOLIPID | PLIN5, PHOSPHO1, PLIN3 | ALDH1A1 524/4885TSHR 1575/4885FASN 174/4885 |
| US-20100104633-A1 | antifungal formulations comprising terbinafine or a pharmaceutically acceptable salt thereof, a lipid, and a surfactant; uses thereof for the treatment of skin and nail fungal infections | DPM1, PIK3C3, NACA | ALDH1A1 3968/4885TSHR 3481/4885FASN 689/4885 |
| US-20100086504-A1 | METHODS OF ADMINISTERING TOPICAL ANTIFUNGAL FORMULATIONS FOR THE TREATMENT OF FUNGAL INFECTIONS | DPM1, ERG28, NACA | ALDH1A1 3533/4885TSHR 3546/4885FASN 289/4885 |
| US-20100197621-A1 | METHODS OF REDUCING THE PROLIFERATION AND VIABILITY OF MICROBIAL AGENTS | MGLL, LIPA, LPO | ALDH1A1 2166/4885TSHR 4213/4885FASN 30/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.